Protocol Ledger

NCT03529110 · Phase III · COMPLETED

DS-8201a Versus T-DM1 for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive, Unresectable and/or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane [DESTINY-Breast03]

Interventional Phase III clinical trial protocol NCT03529110 sponsored by Daiichi Sankyo in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2018-08-09 Enrollment: 524 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT03529110
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)524 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT03529110
Protocol FieldVerified Registry Value
NCT IdentifierNCT03529110
Consolidated Lead SponsorDaiichi Sankyo
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase III
Overall Recruitment StatusCOMPLETED
Registered Enrollment524 participants (ACTUAL)
Registered Start Date2018-08-09
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Daiichi Sankyo across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI